CNTB CONNECT BIOPHARMA HLDGS LTD

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that Zheng Wei, PhD, Co-Founder and CEO of Connect Biopharma will present a corporate update on January 9, at 9:00 am PST, during the upcoming Biotech Showcase taking place in person January 9 – 11, 2023.

Connect Biopharma’s senior leadership team, including Chief Financial Officer, Steven Chan and Chief Medical Officer, Chin Lee, MD, MPH will also be available for meetings with potential investors and partners in San Francisco during the Biotech Showcase / JP Morgan Healthcare Conference week.

Meetings can be requested through the  or by contacting Connect Biopharma at .

About Connect Biopharma Holdings Limited

Connect Biopharma is a U.S. and China-based clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell research. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis and asthma. The Company’s second most advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis. The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with atopic dermatitis.

#BiotechShowcase

INVESTOR CONTACT:

Ina McGuinness

805.427.1372

MEDIA

Deanne Eagle

917.837.5866





EN
19/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONNECT BIOPHARMA HLDGS LTD

 PRESS RELEASE

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundat...

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide Company and Former Cincinnati Bengals Running Back Known for the “Ickey Shuffle” Collaborate to Raise Awareness and Drive Asthma Education with Focus on Acute Attacks SAN DIEGO and CINCINNATI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company) and the (the Foundation) today kicked off a collaboration to expand the Foundation’s asthma education program across the U.S. On this day in 2010, ...

 PRESS RELEASE

Connect Biopharma Reports Second Quarter 2025 Financial Results and Pr...

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update – Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations – – Presented positive data at ATS 2025 and EAACI 2025 supporting the potential of rademikibart to deliver differentiated efficacy and safety in patients with eosinophilic-driven type 2 asthma and COPD – – New drug application for rademikibart for the treatment of AD submitted to China’s NMPA by Simcere, the Company’s exclusive licensee in Greater China – – Announced ...

 PRESS RELEASE

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board...

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors – Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the expansion of the si...

 PRESS RELEASE

Connect Biopharma Announces Plans to Terminate its American Depositary...

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it plans to terminate the Deposit Agreement dated March 18, 2021, as amended, among the Company, Deutsche Bank Trust Company Americas (the “Depositary”), and the holders and beneficial own...

 PRESS RELEASE

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Con...

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29th, 2025 at 9:20 a.m. ET. The live webcast will be available on Connect’s website in the Investors section under ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch